SCHEMBL5475962

SCHEMBL5475962

Cc1cc(C)c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.81
RET P07949 10/20 0.76
FLT3 P36888 6/20 0.73
ALK Q9UM73 5/20 0.73
KDR P35968 4/20 0.73
PDPK1 O15530 2/20 0.73
CSF1R P07333 2/20 0.70
FGFR1 P11362 2/20 0.70
SRC P12931 2/20 0.70
FLT1 P17948 2/20 0.70
FGFR3 P22607 2/20 0.70
MAPK1 P28482 2/20 0.70
FLT4 P35916 2/20 0.70
NTRK1 P04629 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
ABL1 P00519 2/20 0.70
NPC1 O15118 1/20 0.70
GMNN O75496 1/20 0.70
USP2 O75604 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475963 1.00 PDGFRB (0.81) PDGFRBRETFLT3ALKKDR
SCHEMBL4416658 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL31726696 0.84 RET (0.76) PDGFRBRETFLT3ALKKDR
SCHEMBL2126784 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL5478517 0.84 PDPK1 (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL13081086 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL29394706 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL19978 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL19979 0.84 RET (1.00) PDGFRBRETFLT3ALKKDR
SCHEMBL5203211 0.84 PDPK1 (1.00) PDGFRBRETFLT3ALKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
EP-2654799-A1 POLYMER-SUNITINIB CONJUGATES Nektar Therapeutics (US) 2013-10-30 EP disclosed
WO-2012088529-A1 POLYMER-SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed
WO-2012088506-A1 POLYMER-SEMAXANIB MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed
US-20080269212-A1 Amino acid derivatives of indolinone based protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2008-10-30 US disclosed
US-20080193448-A1 Combinations and Methods of Using an Indolinone Compound PFIZER INC. (US) 2008-08-14 US disclosed
US-20080044881-A1 Advanced Indolinone Based Protein Kinase Inhibitors SCRIPPS RESEARCH INSTITUTE, THE 2008-02-21 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 PDGFRB 2159/4885RET 4729/4885FLT3 3095/4885
US-20080193448-A1 Combinations and Methods of Using an Indolinone Compound MDH2, IDH2, MDH1 PDGFRB 3949/4885RET 3619/4885FLT3 843/4885
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 PDGFRB 4421/4885RET 3720/4885FLT3 4311/4885
US-20080269212-A1 Amino acid derivatives of indolinone based protein kinase inhibitors PHKG1, MAP3K20, MKNK1 PDGFRB 817/4885RET 474/4885FLT3 448/4885
US-20080044881-A1 Advanced Indolinone Based Protein Kinase Inhibitors PHKG1, PHKG2, HIPK1 PDGFRB 666/4885RET 671/4885FLT3 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.